High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT ID: NCT03449056
Last Updated: 2019-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
25 participants
INTERVENTIONAL
2019-01-11
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease.
NCT03488628
Effect of High Flow Nasal During Exercise in COPD Patients
NCT03058081
High Flow Nasal Cannula and Hypercapnia
NCT03759457
During-exercise Physiological Effects of Nasal High-flow in Patients With Chronic Obstructive Pulmonary Disease
NCT04014868
Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Healthy Subjects
NCT02495675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TREATMENT
salbutamol nebulization
salbutamol
T2 - T1+1h30: High-nasal flow and salbutamol nebulization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
salbutamol
T2 - T1+1h30: High-nasal flow and salbutamol nebulization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Respiratory rate under 35 breaths/mn
* Glasgow Coma Scale equal to 15,
* indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours),
* NIV sessions spaced more than 6 hours.
Exclusion Criteria
* Contraindication to beta 2 adrenergic agonist;
* Another organ failure (hemodynamic and neurological instability);
* Cardioselective beta-blocker during treatment of copd exacerbation;
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
C.H.U. de Poitiers
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPTINEB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.